Skip to content

Farmaco

Active Private limited companyfounded 2020active for 6 yearsKorenveld 27, 2520 RanstKBO/BCE: BE 0746.369.666

Lifetime

6 annual accounts with figures on one time axis
peak of €22,129 in 2025
€22,129▲ 315%
lowest -€3,151 in 2023
€14,717▲ €15,454
peak of €10,835 in 2021
€1,000▲ 626%
€16,325▲ 241%
Board1 name since 2020
1 director
Documentsfilings and deeds
10-02-2026171 days before the deadline
2025micro format
Gross margin from €5,337 to €22,129Profit of €14,717, after a lossDividend €13,855Equity from €138 to €1,000Debts from €4,789 to €16,325Cash from €1,052 to €1,412

Key points

from the 2025 annual accounts

Equity

€1,000 ▲ 626%
1382024+14,717Profit-13,855Dividend1,0002025

Farmaco paid out €13,855 in dividends. That is 94% of the 2025 profit.

Debts

€16,325 94% of the balance sheet
Suppliers 2%Taxes and wages 11%Other 87%

Of this, €16,041 falls due within a year.

Filings

6 annual accounts 5 late
AprilJune31 JulyOctober202020222024

The 2022 accounts came in latest, 28 days after the end of the period.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,154 companies had the same profile as Farmaco has now. Each dot stands for 6 companies, two years later.

96.0%
were still trading
2.3%
stopped another way
1.7%
went bankrupt
  • Micro
  • 5 to 10 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,154 companies, not a prediction for Farmaco. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 50 sharesdeed of 21-04-2020
  • 50 sharesdeed of 21-04-2020
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0746369666
Incorporation Founding capital of €1,000, 100 shares · Founded by and · appointed as director · published on 21-04-2020 · Gazette deed
First establishment Korenveld 27, Ranst
All 11 events

Comparable companies

same main activity, similar in size and age
Company
Farmaco Ranst €17,325 €22,129 5.8% -
PHARMAXUS Zandhoven €25,186 €19,190 26.0% -
JL PHARMA Stoumont €22,608 €15,096 47.5% -
LORENA BOULANGER PHARMA Chapelle-lez-Herlaimont €32,165 €14,597 80.6% -
GRACE PARTNER Quaregnon €19,066 €17,089 38.6% -
DEL PHARMA Mons €36,943 €19,174 44.1% -
CAMILLE HUBY Etterbeek €18,562 €10,507 77.8% -

These companies have the same main activity as Farmaco: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €18,600 and €36,900, founded between 2018 and 2024.

Official details

Source: KBO
Status
Active since 17-04-2020Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Establishment unit
2.301.376.4682520 Ranst, since 17-04-2020
Financial year end
31 December
Peppol
Reachable since 02-01-2026
Company details

Annual accounts 2025

≈ €230,000estimated
€17,325▲ 252%
Filing
Filed on 10-02-2026, 171 days before the end of the filing period
Financials

Insights on Farmaco

Farmaco files the micro format. That format states no turnover. The gross margin rose from €10,953 in 2020 to €22,129 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Farmaco

What is the company number of Farmaco?
The company number of Farmaco is 0746.369.666. The VAT number is the same number with BE in front: BE 0746.369.666.
Where is Farmaco based?
The registered office is at Korenveld 27, 2520 Ranst.Company details
What does Farmaco do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of Farmaco?
Farmaco is a private limited company (BV).
When was Farmaco founded?
Farmaco was founded on 17-04-2020.
Is Farmaco still active?
Yes, Farmaco is an active enterprise in the KBO register.
What is the turnover of Farmaco?
The turnover in financial year 2025 is ≈ €230,000. This figure is estimated from the gross margin of €22,129 and 139 comparable companies (NACE 477). It probably lies between €85,000 and €500,000. It is a rough estimate.Financials
Is Farmaco profitable?
In financial year 2025, Farmaco made a profit of €14,717.
Where can I find the annual accounts of Farmaco?
Farmaco filed 6 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Farmaco due?
Farmaco must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.